Altiratinib

Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.

Product Specifications

CAS Number

[1345847-93-9]

Product Name Alternative

DCC-2701

UNSPSC

12352005

Hazard Statement

H315, H317, H318, H334, H335, H341, H361, H370, H413

Target

C-Met/HGFR; FLT3; Trk Receptor; VEGFR

Type

Reference compound

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Altiratinib.html

Purity

99.29

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC(F)=C(OC4=CC(NC(C5CC5)=O)=NC=C4)C=C3F

Molecular Formula

C26H21F3N4O4

Molecular Weight

510.46

Precautions

H315, H317, H318, H334, H335, H341, H361, H370, H413

References & Citations

[1]Smith BD, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated DrugResistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015 Sep;14 (9) :2023-34.